SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

BBOT

BridgeBio Oncology Therapeutics, Inc.
NASDAQHealth Care

Latest close: 2.82 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 8, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 11, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
  3. Aug 11, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record16612 flagged findings
Reported transactions (Form 4)68since Feb 13, 2024 · and 26 other holdings
Corporate events (8-K)16since Feb 14, 2024

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

Identity

Formerly traded as HLXB.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 166)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Insider transaction · 5 Form 4 filingsshow all 5hide
  • Sep 8, 268-K ↗Current report · Other events
  • Sep 1, 26S-3 ↗Securities offering
  • Sep 1, 26POS AM ↗Securities offering
  • Aug 12, 26424B3 ↗Securities offering
  • Aug 11, 2610-Q ↗Quarterly report
  • Aug 11, 268-K ↗Current report · Results
  • Jul 6, 26SCHEDULE 13D/A ↗Stake with intent to influence · Bihua Chen · 22.3% · event on Jul 1, 26 · amendment
  • Insider transaction · 5 Form 4 filingsshow all 5hide
  • Jun 22, 26424B3 ↗Securities offering
  • Jun 22, 268-K ↗Current report · A senior executive left or was appointed
  • Insider transaction · 6 Form 4 filingsshow all 6hide

166 filings on record, the oldest from Jan 10, 24.

Listing the 25 most recent filings of the 166 on record.

8-Ks, explained

Structure7Governance9
  • Governance4 senior executive changes2026show all 4hide
    • Jun 22, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Apr 29, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Apr 23, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Mar 26, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Aug 13, 25StructureEntered a material agreement+12 more in the same filing8-K 1.01 ↗
  • Mar 3, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Feb 10, 25GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Feb 14, 24StructureEntered a material agreement+5 more in the same filing8-K 1.01 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Bihua Chen22.3%Jul 1, 26SCHEDULE 13D/A ↗8 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • BridgeBio Pharma LLC17.5%Aug 11, 25SCHEDULE 13D ↗2 co-filers on this document — the figure is the largest single stake, not their sum.

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • BlackRock Portfolio Management LLC7.9%Mar 31, 25SCHEDULE 13G ↗
  • Deerfield Management Company, L.P.6.2%Aug 11, 25SCHEDULE 13G ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
  • BC Global Opportunities IX LP5.5%Sep 4, 25SCHEDULE 13G ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Sculptor Capital LP5.1%Jul 17, 25SCHEDULE 13G ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
  • Millennium Management LLC4.7%Jun 30, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
show 2 more holdershide
  • Citadel Advisors LLC3.2%Sep 30, 25SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
  • Adage Capital Management, L.P.1.9%Sep 30, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Feb 13, 24Buy$694KBihua ChenCEO and Chairperson↗
  • Feb 13, 24Buy$14.3MBihua ChenCEO and Chairperson↗
  • Feb 13, 24Buy$9.0MBihua ChenCEO and Chairperson↗
Stock compensation, tax and giftsshow the 34 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Oct 1, 26Tax$4KYong BenChief Med & Dev Officer↗
  • Oct 1, 26Tax$4KPedro BeltranPresident and CEO↗
  • Oct 1, 26Tax$1KIdan ElmelechCOO & Principal Financial Ofcr↗
  • Oct 1, 26Tax$496Marc CoboPrincipal Accounting Officer↗
  • Sep 10, 26Compensationamount n/aMarc CoboPrincipal Accounting Officer↗
  • Sep 10, 26Tax$1KMarc CoboPrincipal Accounting Officer↗
  • Jul 1, 26Tax$8KPedro BeltranPresident and CEO↗
  • Jul 1, 26Tax$8KYong BenChief Med & Dev Officer↗
  • Jul 1, 26Tax$3KIdan ElmelechCOO & Principal Financial Ofcr↗
  • Jul 1, 26Tax$975Marc CoboPrincipal Accounting Officer↗
  • Jul 1, 26Otheramount n/aBihua Chen↗
  • Jul 1, 26Otheramount n/aBihua Chen↗
  • Jul 1, 26Otheramount n/aBihua Chen↗
  • Jul 1, 26Otheramount n/aBihua Chen↗
  • Apr 1, 26Tax$5KUneek Mehra↗
  • Apr 1, 26Tax$9KPedro BeltranPresident and CEO↗
  • Apr 1, 26Tax$9KYong BenChief Med & Dev Officer↗
  • Mar 10, 26Compensationamount n/aYong BenChief Med & Dev Officer↗
  • Mar 10, 26Compensationamount n/aPedro BeltranChief Scientific Officer↗
  • Mar 10, 26Compensationamount n/aUneek MehraChief Financial Officer↗
  • Oct 10, 25Otheramount n/aBridgeBio Pharma LLC↗
  • Aug 11, 25Compensationamount n/aJohn P. Schmid↗
  • Aug 11, 25Compensationamount n/aMark C. McKenna↗
  • Aug 11, 25Compensationamount n/aAlbert A Holman III↗
  • Aug 11, 25Compensationamount n/aBihua Chen↗
  • Aug 11, 25Otheramount n/aBihua Chen↗
  • Aug 11, 25Compensation$8.2MBihua Chen↗
  • Aug 11, 25Compensation$6.8MBihua Chen↗
  • Aug 11, 25Compensation$60.0MBihua Chen↗
  • Aug 11, 25Compensationamount n/aBihua Chen↗
  • Aug 11, 25Compensationamount n/aBihua Chen↗
  • Aug 11, 25Compensationamount n/aBihua Chen↗
  • Feb 13, 24Compensation$5.1MHelix Holdings II LLC↗
  • Feb 13, 24Compensation$5.1MBihua ChenCEO and Chairperson↗

The full record holds 37 transactions and goes back to Feb 8, 24.

Its sector and its market

BridgeBio Oncology Therapeutics, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From BridgeBio Oncology Therapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow BridgeBio Oncology Therapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
166 documents on file, from Jan 10, 2024 to Oct 5, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.